Overview

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Status:
Recruiting

Trial end date:
2023-03-10

Target enrollment:

Participant gender:

Summary

This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Processa Pharmaceuticals

Treatments:

Capecitabine